{
    "clinical_study": {
        "@rank": "120929", 
        "arm_group": [
            {
                "arm_group_label": "No antiviral arm", 
                "arm_group_type": "No Intervention", 
                "description": "provide standard of care to mothers and standard immunoprophylaxis to their infants"
            }, 
            {
                "arm_group_label": "Lamivudine", 
                "arm_group_type": "Experimental", 
                "description": "lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants"
            }, 
            {
                "arm_group_label": "Telbivudine", 
                "arm_group_type": "Experimental", 
                "description": "Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants"
            }
        ], 
        "brief_summary": {
            "textblock": "To explore the antiviral effect of nucleoside analogue in late pregnancy and the safety of\n      the antiviral drug to fetus.To establish the best therapy strategy to pregnant women with\n      high level of HBV DNA."
        }, 
        "brief_title": "Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hepatitis B Infection", 
            "Chronic Infection", 
            "Viremia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Viremia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Telbivudine and Lamivudine,a preganancy category B medication,reduces HBV DNA and normalizes\n      serum ALT in chronic hepatitis B patients with few adverse effects.Two aspects on the drug\n      use in pregnancy will be evaluated prospectively in this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        HBeAg+CHB pregnant woman gestational age 28 weeks HBV-DNA>log10 copies/ml\n\n        Exclusion Criteria:\n\n        co-infection with hepatitis A,C,D,E or HIV evidence of hepatocellular carcinoma\n        decompensated liver disease or significant co-morbidity concurrent treatment with\n        immune-modulators,cytotoxic drugs,or steroids clinical signs of threatened miscarriage in\n        early prenancy evidence of fetal deformity by ultrasound examination the biological father\n        of the child had CHB"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "700", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01788371", 
            "org_study_id": "2011.6"
        }, 
        "intervention": [
            {
                "arm_group_label": "Telbivudine", 
                "description": "About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun", 
                "intervention_name": "Telbivudine", 
                "intervention_type": "Drug", 
                "other_name": "Telbivudine"
            }, 
            {
                "arm_group_label": "Lamivudine", 
                "description": "About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum", 
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug", 
                "other_name": "lamivudine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lamivudine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 29, 2013", 
        "number_of_arms": "3", 
        "official_title": "Nucleoside Analogue in Late Preganancy to Prevent Vertical Transmission of Hepatitis B Virus", 
        "overall_official": {
            "affiliation": "Beijing YouAn Hospital", 
            "last_name": "Hua Zhang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "The data on its tolerability and safety in HBeAg+ pregnant woman with HBV DNA>6log10 copies/Ml during late pregnancy and infants", 
                "safety_issue": "Yes", 
                "time_frame": "perinatal to 28 weeks after infant delivery"
            }, 
            {
                "measure": "Its efficacy in the reduction of HBV vertical transmission rate", 
                "safety_issue": "Yes", 
                "time_frame": "perinatal to 28 weeks after infant delivery"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01788371"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beijing YouAn Hospital", 
            "investigator_full_name": "Hua Zhang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Maternal DNA reduction,ALT normalization, and loss/seroconversion of HBeAg or HBsAg", 
            "safety_issue": "Yes", 
            "time_frame": "perinatal to 28 weeks of postpartum"
        }, 
        "source": "Beijing YouAn Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Mount Sinai School of Medicine", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Hua Zhang", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2009", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}